ESR1 and breast cancer: The 21-gene assay Oncotype DX® Breast Recurrence Score (RS), has been used widely to guide adjuvant chemotherapy utilizations in patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2) negative node-negative breast cancer (BC) (1–4), and are part of international consensus guidelines.